| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
RCC1 and BTB domain containing protein 1 | 0.572 | 0.692 | 1.6E-06 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
V-set immunoregulatory receptor | 0.573 | 0.654 | 0.76 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
zyg-11 family member A, cell cycle regulator | 0.861 | 0.115 | 1.3E-11 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
RAB37, member RAS oncogene family | 0.760 | 0.231 | 8.1E-08 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
chromosome 22 open reading frame 34 | 0.931 | 0.038 | 1.4E-04 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
potassium calcium-activated channel subfamily N member 4 | 0.653 | 0.577 | 5.0E-07 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
cancer susceptibility 15 | 0.603 | 0.577 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||
|
lymphocyte specific protein 1 | 0.700 | 0.462 | 1.5E-06 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
lysozyme | 0.526 | 0.846 | 3.4E-06 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
ARVCF delta catenin family member | 0.540 | 0.769 | 5.0E-11 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
activating transcription factor 3 | 0.494 | 0.885 | 8.9E-02 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2019 | 2019 | ||||||||
|
nuclear factor I X | 0.547 | 0.769 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
NFKB inhibitor epsilon | 0.700 | 0.385 | 0.77 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
ninjurin 2 | 0.751 | 0.269 | 1.1E-03 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
p21 (RAC1) activated kinase 2 | 0.653 | 0.538 | 0.97 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
platelet derived growth factor receptor beta | 0.416 | 0.846 | 0.90 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
casein kinase 1 gamma 1 | 1.000 | 0.038 | 1.00 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
major histocompatibility complex, class II, DP beta 1 | 0.453 | 0.923 | 5.3E-10 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
phosphoribosyl transferase domain containing 1 | 0.805 | 0.385 | 2.4E-13 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
ecotropic viral integration site 5 | 0.743 | 0.346 | 2.0E-11 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
ankyrin repeat domain 55 | 0.650 | 0.462 | 6.8E-08 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
triggering receptor expressed on myeloid cells like 2 | 0.861 | 0.192 | 1.1E-09 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
RNA polymerase II associated protein 2 | 1.000 | 0.077 | 2.6E-07 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
stearoyl-CoA desaturase 5 | 0.682 | 0.654 | 1.0E-03 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | ||||||||
|
vacuole membrane protein 1 | 0.674 | 0.462 | 0.96 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 |